-+ 0.00%
-+ 0.00%
-+ 0.00%

CureVac Reports Q2 Revenues Of EUR1.2M, Lower Than EUR14.4M YoY

Benzinga·08/15/2025 11:58:01
Listen to the news

The decrease year-over-year was primarily driven by lower revenues from GSK following the restructuring of the partnership in July 2024 from a Collaboration into a Licensing Agreement as well as lower sales to CRISPR Therapeutics.